Lazard Asset Management
KPTI icon

Lazard Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Lazard Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105
Closed -$1K – 2411
2024
Q3 		$1K Buy
+105
New +$1.3K ﹤0.01% 2168
2023
Q3 		– Sell
-67
Closed -$1K – 2381
2023
Q2 		$1K Hold
67
– – ﹤0.01% 2255
2023
Q1 		$3K Hold
67
– – ﹤0.01% 2188
2022
Q4 		$3K Hold
67
– – ﹤0.01% 2271
2022
Q3 		$5K Hold
67
– – ﹤0.01% 2183
2022
Q2 		$4K Sell
67
-1,582
-96% -$145K ﹤0.01% 2262
2022
Q1 		$182K Sell
1,649
-454
-22% -$56.6K ﹤0.01% 1273
2021
Q4 		$202K Buy
+2,103
New +$210K ﹤0.01% 1279
2021
Q3 		– Sell
-382
Closed -$59K – 2222
2021
Q2 		$59K Sell
382
-115
-23% -$16.7K ﹤0.01% 1532
2021
Q1 		$78K Sell
497
-1,559
-76% -$328K ﹤0.01% 1267
2020
Q4 		$477K Buy
+2,056
New +$476K ﹤0.01% 982
2020
Q2 		– Sell
-198
Closed -$57K – 1705
2020
Q1 		$57K Buy
+198
New +$54.6K ﹤0.01% 1131

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Lazard Asset Management's KPTI Position: Q4 2024 in Review

Lazard Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 105 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in KPTI in Q1 2020 and held it in 12 quarters. The position peaked at $477K in Q4 2020. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

  • Lazard Asset Management reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lazard Asset Management sold 105 Karyopharm Therapeutics shares in Q4 2024, an estimated $1K.
  • Lazard Asset Management first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 12 quarters.
  • Lazard Asset Management's Karyopharm Therapeutics position peaked at $477K in Q4 2020.
  • 87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.